[go: up one dir, main page]

IN2012DN01254A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01254A
IN2012DN01254A IN1254DEN2012A IN2012DN01254A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A IN 1254DEN2012 A IN1254DEN2012 A IN 1254DEN2012A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A
Authority
IN
India
Prior art keywords
compounds
enteralor
ainfections
isozazole
substituents
Prior art date
Application number
Inventor
Yitsun Richard Kao
Dan Yang
Kwokyung Yuen
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of IN2012DN01254A publication Critical patent/IN2012DN01254A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compounds which exhibit antiviral activity, particularly against influenza virus,and methods of making and using there of are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteralor parenteral administration. The compounds are preferably used to treat or prevent Influenza Ainfections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.
IN1254DEN2012 2009-08-05 2010-08-05 IN2012DN01254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23143109P 2009-08-05 2009-08-05
PCT/CN2010/001187 WO2011015037A1 (en) 2009-08-05 2010-08-05 Antiviral compounds and methods of making and using there of cross reference to related applications

Publications (1)

Publication Number Publication Date
IN2012DN01254A true IN2012DN01254A (en) 2015-05-15

Family

ID=43543887

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1254DEN2012 IN2012DN01254A (en) 2009-08-05 2010-08-05

Country Status (13)

Country Link
EP (1) EP2462138B1 (en)
JP (1) JP2013501008A (en)
KR (1) KR20120092567A (en)
CN (1) CN102596946B (en)
AU (1) AU2010281265A1 (en)
BR (1) BR112012002331A2 (en)
CA (1) CA2770140A1 (en)
IL (1) IL217745A0 (en)
IN (1) IN2012DN01254A (en)
MX (1) MX2012001504A (en)
RU (1) RU2012104214A (en)
SG (1) SG178106A1 (en)
WO (1) WO2011015037A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011147198A1 (en) * 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
CN103201268B (en) 2010-09-08 2015-08-12 百时美施贵宝公司 As the novel piperazine analogue of wide spectrum influenza virus medicine
BR112013007651A2 (en) * 2010-09-28 2019-09-24 Bristol-Myers Squibb Company piperazine analogues with substituted heteroaryl groups as broad spectrum influenza antivirals
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20140011700A1 (en) * 2011-03-25 2014-01-09 Bristol-Myers Squibb Company Three-dimensional structure of h1n1 nucleoprotein in complex with antiviral compounds
KR101369584B1 (en) * 2011-04-19 2014-03-06 일양약품주식회사 Phenyl-isoxazol derivatives and preparation process thereof
CN102432555A (en) * 2011-09-09 2012-05-02 中国科学院广州生物医药与健康研究院 1,2, 3-triazole-4 (5) carboxamide compound and application thereof
AU2013234080B2 (en) 2012-03-13 2016-12-22 Respivert Limited Novel pharmaceutical formulations
US9676734B2 (en) 2012-05-18 2017-06-13 Vironova Influenza Ab Compounds and methods
JP6484168B2 (en) * 2012-05-18 2019-03-13 ヴィロノヴァ・インフルエンザ・アクチェボラーグ Methanethione compounds with antiviral activity
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR095353A1 (en) 2013-03-15 2015-10-07 Respivert Ltd COMPOUND
JO3279B1 (en) 2013-03-15 2018-09-16 Respivert Ltd 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
LT2986610T (en) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
US20160168124A1 (en) * 2013-07-30 2016-06-16 Janssen Sciences Ireland Uc Substituted pyridine-piperazinyl analogues as rsv antiviral compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CN107056762B (en) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 Bis-carbonyl analogues for use against influenza virus
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
US11040963B2 (en) 2017-02-02 2021-06-22 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibitions
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
TWI793151B (en) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
HRP20231295T1 (en) 2018-07-10 2024-02-02 Novartis Ag 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2) DEPENDENT DISEASES
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
CA3125767A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI765323B (en) * 2019-08-22 2022-05-21 大陸商四川海思科製藥有限公司 Anti-influenza virus compound and preparation method and use thereof
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (en) 2019-10-14 2022-10-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI775313B (en) 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
SI4106876T1 (en) 2020-02-18 2025-11-28 Gilead Sciences, Inc. Antiviral compounds
TWI883391B (en) 2020-02-18 2025-05-11 美商基利科學股份有限公司 Antiviral compounds
WO2021204923A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Antiviral agents
WO2021204924A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Compounds for use in the treatment of hypercytokinemia
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP7688152B2 (en) 2021-04-16 2025-06-03 ギリアード サイエンシーズ, インコーポレイテッド Method for preparing carbanucleosides using amides
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
AR126101A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117150A (en) 1991-10-25 1993-05-14 Sanwa Kagaku Kenkyusho Co Ltd Antiviral agent
KR200293242Y1 (en) * 2002-04-18 2002-11-01 전이범 Oxygen cutting hose
DE10236564A1 (en) * 2002-08-08 2004-05-19 Ursapharm Arzneimittel Gmbh & Co. Kg Use of papaverine-like vasodilator and pharmaceutical composition
CA2597430C (en) * 2005-02-17 2014-08-05 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
EP2462138A1 (en) 2012-06-13
EP2462138B1 (en) 2014-09-24
MX2012001504A (en) 2012-06-01
BR112012002331A2 (en) 2019-09-24
CA2770140A1 (en) 2011-02-10
AU2010281265A2 (en) 2012-04-05
CN102596946A (en) 2012-07-18
IL217745A0 (en) 2012-03-29
JP2013501008A (en) 2013-01-10
EP2462138A4 (en) 2013-01-23
SG178106A1 (en) 2012-03-29
WO2011015037A1 (en) 2011-02-10
CN102596946B (en) 2015-06-17
KR20120092567A (en) 2012-08-21
AU2010281265A1 (en) 2012-03-22
RU2012104214A (en) 2013-09-10

Similar Documents

Publication Publication Date Title
IN2012DN01254A (en)
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PE20160127A1 (en) ACID COMPOUND (2S, 3S) -3 - ((2- (5-FLUORO-1H-PIRROLO [2,3-B] PYRIDIN-3-IL) -5-FLUOROPYRIMIDIN-4-IL) AMINO) BICICLO [2.2. 2] OCTANE-2-CARBOXYL AS AN INHIBITOR OF THE REPLICATION OF THE FLU VIRUS TO H1N1, H2N2, H3N2 or H5N1
EA201391127A1 (en) C-17 AND C-3 MODIFIED TRITERPENOIDS WITH INHIBITOR ACTIVITY OF HIV MATURATION
EA201270800A1 (en) C-28 AMIDES OF MODIFIED DERIVATIVES OF C-3 BETULINIC ACID AS AN HIV INHIBITORS INHIBITORS
UA113956C2 (en) PIRIMIDIN DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
JO3419B1 (en) Pyridopyrazine anticancer compounds through inhibition of FGFR kinase enzymes
UY34350A (en) DERIVATIVES OF PIRAZOLQUINOLINONA, ITS PREPARATION AND THERAPEUTIC USE.
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
UA114476C2 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX2013007104A (en) BICYCLE DERIVATIVES [3,2,1] OCTILAMIDE AND ITS USES.
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2015014816A (en) Microrna compounds and methods for modulating mir-122.
IL321503A (en) Recombinant virus, preparations containing it and its uses
BR112015013463A8 (en) INDOL CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
EA201490643A1 (en) NEW BETULINIC ACID DERIVATIVES WITH ANTI-VIRUS ACTIVITY
BR112014017735A8 (en) HETEROCYCLIC AMIDE DERIVATIVE COMPOUNDS AS P2X7 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND
UY34314A (en) DERIVATIVES OF ANILINA, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION.
JOP20170029B1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
EA201190236A1 (en) NEW DERIVATIVES OF STEROID COMPOUNDS [3,2-C] PYRAZOLS WITH GLUCOCORTICOID ACTIVITY
RU2012124039A (en) TREATMENT OF MICROBIAL INFECTIONS
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
ECSP13013080A (en) USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
IN2011CH03893A (en)
EA201370058A1 (en) MEANS AGAINST FLU VIRUS B